Edition:
United States

Cardiovascular Systems Inc (CSII.OQ)

CSII.OQ on NASDAQ Stock Exchange Global Select Market

28.74USD
13 Dec 2018
Change (% chg)

-- (--)
Prev Close
$28.74
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
83,410
52-wk High
$40.00
52-wk Low
$20.59

Summary

Name Age Since Current Position

Scott Ward

58 2016 Chairman of the Board, President, Chief Executive Officer

Jeffrey Points

41 2018 Chief Financial Officer

Rhonda Robb

50 2018 Chief Operating Officer

Sandra Sedo

54 2016 Chief Compliance Officer

Alexander Rosenstein

46 2015 General Counsel and Corporate Secretary

Laura Gillund

57 2013 Chief Talent Officer

Martha Aronson

51 2017 Independent Director

Scott Bartos

55 2012 Independent Director

Brent Blackey

59 2007 Independent Director

Edward Brown

55 2009 Independent Director

William Cohn

58 2015 Independent Director

Augustine Lawlor

62 2009 Independent Director

Jack Nielsen

Vice President, Investor Relations & Corporate Communications

Biographies

Name Description

Scott Ward

Mr. Scott R. Ward serves as Chairman of the Board, President, Chief Executive Officer of the Company. Mr. Ward has been a member of our Board since November 2013 and has served as its Chairman since November 2014. Mr. Ward served as our Interim President and Chief Executive Officer beginning November 30, 2015, and on August 15, 2016, Mr. Ward was appointed as our President and Chief Executive Officer. Since 2013, Mr. Ward has been one of the Managing Directors at SightLine Partners. Following his appointment as our President and Chief Executive Officer, Mr. Ward continues to be a Managing Director of SightLine Opportunity Management Fund II, LLC and may provide limited advisory and consulting services to SightLine Partners in this capacity. From 1981 to 2010, Mr. Ward was employed by Medtronic, Inc. and held a number of senior leadership positions. Mr. Ward was Senior Vice President and President of Medtronic’s CardioVascular business from May 2007 to November 2010. Prior to that he was Senior Vice President and President of Medtronic’s Vascular business from May 2004 to May 2007, Senior Vice President and President of Medtronic’s Neurological and Diabetes Business, from February 2002 to May 2004, and was President of Medtronic’s Neurological business from January 2000 to January 2002. He was Vice President and General Manager of Medtronic’s Drug Delivery Business from 1995 to 2000. Prior to that, Mr. Ward led Medtronic’s Neurological Ventures in the successful development of new therapies. Mr. Ward serves on the boards of several private companies. Until April 2016, Mr. Ward was the Chairman of the Board of Creganna Medical. Mr. Ward served as a member of the Board of Surmodics, Inc. from September 2010 to March 2015. We believe that Mr. Ward’s experience running businesses within a large medical device company and his knowledge of the medical device industry allow him to make a valuable contribution to our Board.

Jeffrey Points

Mr. Jeffrey Points is Chief Financial Officer of the company. Mr. Points joined us in September 2007 as Corporate Controller, became Senior Director and Controller in July 2013, Corporate Controller and Treasurer in January 2015, Vice President, Corporate Controller and Treasurer in May 2017 and was promoted to Chief Financial Officer in February 2018. From July 2005 to September 2007, Mr. Points was Assistant Controller at Empi, a manufacturer and provider of non-invasive medical products for pain management and physical rehabilitation. From January 1998 to July 2005, Mr. Points held various leadership positions at CliftonLarsonAllen, a national public accounting firm. Mr. Points also serves as a member of the Board of Directors for The Phoenix Residence, Inc.

Rhonda Robb

Ms. Rhonda J. Robb is Chief Operating Officer of the company. Ms. Robb joined us as Chief Operating Officer in January 2018. Prior to joining us, she held several positions at Medtronic, most recently as Vice President and General Manager of the Heart Valve Therapies Business from 2014 to 2018. From 2009 to 2014, Ms. Robb was Vice President and General Manager for Medtronic’s Catheter Based Therapies business. Ms. Robb was employed by Medtronic since 1990 and has served in several other leadership roles, including Vice President of Global Marketing, Coronary and Peripheral; Director Global Marketing, Heart Failure/High Power Therapies; and Director US Marketing, Cardiac Rhythm & Disease Management.

Sandra Sedo

Ms. Sandra Marie Sedo serves as Chief Compliance Officer of the Company. Ms. Sedo joined us in June 2016 as Corporate Compliance Officer, and was promoted to Chief Compliance Officer in July 2017. Prior to joining us, Ms. Sedo consulted for medical device companies in the legal and compliance areas. From 2005 to 2015, Ms. Sedo was employed by Medtronic, Inc. in various legal and compliance roles, and prior to that was a partner at Dorsey & Whitney LLP, which provides legal services to us from time to time.

Alexander Rosenstein

Mr. Alexander Rosenstein is General Counsel and Corporate Secretary of the Company. Mr. Rosenstein joined us in September 2014 as Corporate Legal and Compliance Counsel, became Corporate Secretary in November 2014, and was promoted to General Counsel in March 2015. From October 2005 to September 2014, Mr. Rosenstein was an attorney at Fredrikson & Byron, P.A., which provides legal services to us from time to time, and from September 1998 to September 2005, he was an attorney practicing in New York City.

Laura Gillund

Ms. Laura J. Gillund serves as Chief Talent Officer of the company. Ms. Gillund joined us in September 2013 as Vice President of Human Resources and Professional Development and was promoted to Chief Talent Officer in April 2016. Previously, Ms. Gillund was Vice President of Human Resources for C.H. Robinson Worldwide, Inc. from August 2002 to May 2012. Ms. Gillund serves as a member of the Board of Allina Health System and as member of the Board of Directors of College Possible.

Martha Aronson

Ms. Martha Goldberg Aronson serves as an Independent Director of the Company. Ms. Goldberg Aronson has been a member of our Board since February 2017. Ms. Goldberg Aronson served as Executive Vice President of Strategic Planning at Ecolab, Inc., a specialty chemical company, from November 2015 to April 2016, and previously served as Ecolab’s Executive Vice President and President-Global Healthcare, from September 2012 to November 2015. Prior to Ecolab, Ms. Goldberg Aronson served as Senior Vice President and President, North America, of Hill-Rom Holdings, Inc., a leading worldwide manufacturer and provider of medical technologies and related services for the health-care industry, since August 2010. Before joining Hill-Rom, she served as Senior Vice President at Medtronic, Inc., from March 2008 to November 2009, and in various other domestic and international management positions with Medtronic, since 1991. She is also a director of Methode Electronics, Inc., CONMED Corporation and Clinical Innovations, LLC, and previously served as a director of Hutchinson Technology from 2010 to 2016, when it was acquired. We believe that Ms. Goldberg Aronson’s leadership experience at companies within the healthcare industry and knowledge of the medical device industry make her a valuable contributor to our Board.

Scott Bartos

Mr. Scott A. Bartos is an Independent Director of the company. Mr. Bartos has been a member of our Board since October 2012. Mr. Bartos has more than 25 years of experience as a healthcare executive and director, and is currently a director of Outset Medical (f/k/a Home Dialysis Plus). He previously served as a director of Alliance HealthCare Services, Inc. until its sale in August 2017. He also previously served as President & CEO and chairman of the board of directors of Rural/Metro Corporation. Rural/Metro Corporation filed for bankruptcy in August 2013, and Mr. Bartos was hired to lead the turnaround effort in connection with this bankruptcy. Rural/Metro was acquired in October 2015. Mr. Bartos previously served as President, Chief Executive Officer, and a director of LaVie Care Centers, a national long-term care company with revenues exceeding $1.0 billion annually, from July 2009 through the sale of the company in December 2011. From December 2008 to July 2009, he was an Executive in Residence at Warburg Pincus LLC. Mr. Bartos was Division President for Gambro Healthcare, Inc. from 2000 to 2004 and COO-East from 2004 to 2005. Mr. Bartos previously was the founder, President, CEO and a Director of Endoscopy Specialists Inc. We believe that Mr. Bartos’ experience in business design, strategic planning, new product and service innovation, sales and marketing, and mergers and acquisitions with large, medium and small businesses in both public and private company settings allow him to make valuable contributions to our Board.

Brent Blackey

Mr. Brent G. Blackey is an Independent Director of the Company. Mr. Blackey has been a member of our Board since October 2007. Mr. Blackey served as the President and Chief Operating Officer for Holiday Companies from December 2004 until December 2017, when it was sold to Alimentation Couche-Tard. Between 2002 and 2004, Mr. Blackey was a Senior Partner at the accounting firm of Ernst & Young LLP. Prior to 2002, Mr. Blackey served as a Senior Partner at the accounting firm of Arthur Andersen LLP. Mr. Blackey has served on the board of directors of Coborn’s Inc. since January 2018 and the advisory boards of Northern Tool and Equipment Company, Inc. and Oppidan, Inc. since December 2017. Mr. Blackey served on the board of directors of Datalink Corporation, a publicly-held company, from April 2006 until it was sold in January 2017. Mr. Blackey also serves on the Board of Overseers for the University of Minnesota’s Carlson School of Management. We believe that Mr. Blackey’s accounting background, experience as an executive officer and his service as a board member of a public company are strong endorsements for membership on our Board and invaluable to his role as our audit committee financial expert and Chairman of the Audit, Risk Management and Finance Committee.

Edward Brown

Mr. Edward M. Brown is Independent Director of the Company. Mr. Brown has been a member of our Board since February 2009. Mr. Brown was a member of the board of directors of Replidyne, Inc. from May 2007 to February 2009. Mr. Brown was appointed as our Lead Independent Director in August 2016. Mr. Brown currently serves as Managing Director at Five Arrows Capital Partners, an affiliate of the Rothschild Group. Mr. Brown was previously a Partner at Health Evolution Partners from 2010 to 2016, Managing Director at TPG Biotech from 2007 to 2009 and a Managing Director and co-founder of Healthcare Investment Partners, a private equity fund focused on healthcare investments, from 2004 to 2007. Before Healthcare Investment Partners, Mr. Brown was a Managing Director in the healthcare group of Credit Suisse Group where he led the firm’s West Coast healthcare effort and was one of the senior partners responsible for the firm’s global life sciences practice. Mr. Brown has previously served on the boards of various public and private companies. We believe that Mr. Brown’s leadership experience in life sciences and strategic transactions and his service as a board member of public and private healthcare companies enable him to bring valuable insight and knowledge to our Board.

William Cohn

Dr. William E. Cohn M.D. is Independent Director of the Company. Dr. Cohn has been a member of our Board since February 2015. Dr. Cohn is a Vice President of Medical Devices and Director of the Center for Device Innovation at Johnson & Johnson. He is also a Cardiothoracic Surgeon and a professor of Surgery at Baylor College of Medicine. Dr. Cohn is the chief medical officer of BiVACOR USA, a privately-held medical device company. In addition to being the only physician on our Board, we believe Dr. Cohn’s active involvement in the development, implementation, and regulatory clearance for several medical devices in cardiovascular medicine make him a valuable contributor to our Board and mission.

Augustine Lawlor

Mr. Augustine J. Lawlor is an Independent Director of the Company. Mr. Lawlor has been a member of our Board since February 2009. He was a member of the board of directors of Replidyne, Inc. from March 2002 to February 2009. Mr. Lawlor is the Managing Partner of HealthCare Ventures LLC, where he was a Managing Director from 2000 to 2007. Mr. Lawlor is also the Chief Operating Officer of Leap Therapeutics. Mr. Lawlor was previously Chief Operating Officer of LeukoSite, Inc. and has also served as a management consultant with KPMG Peat Marwick. Mr. Lawlor serves on the board of directors of Catalyst Biosciences, Inc., as well as several private companies. He also served on the board of directors of Human Genome Sciences, Inc. from March 2004 to August 2012. We believe that Mr. Lawlor’s leadership experience in operating companies and with investment firms and his service as a board member of public companies enable him to bring valuable insight and knowledge to our Board.

Jack Nielsen

Basic Compensation

Name Fiscal Year Total

Scott Ward

3,448,340

Jeffrey Points

617,271

Rhonda Robb

2,504,850

Sandra Sedo

--

Alexander Rosenstein

711,736

Laura Gillund

814,302

Martha Aronson

190,000

Scott Bartos

190,000

Brent Blackey

190,000

Edward Brown

230,000

William Cohn

180,000

Augustine Lawlor

200,000

Jack Nielsen

--
As Of  29 Jun 2018